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Background to the debate: The human rights responsi-
bilities of drug companies have been considered for years
by nongovernmental organizations, but were most
sharply defined in a report by the UN Special Rapporteur
on the right to health, submitted to the United Nations
General Assembly in August 2008. The ‘‘Human Rights
Guidelines for Pharmaceutical Companies in relation to
Access to Medicines’’ include responsibilities for transpar-
ency, management, monitoring and accountability, pric-
ing, and ethical marketing, and against lobbying for more
protection in intellectual property laws, applying for
patents for trivial modifications of existing medicines,
inappropriate drug promotion, and excessive pricing. Two
years after the release of the Guidelines, the PLoS Medicine
Debate asks whether drug companies are living up to
their human rights responsibilities. Sofia Gruskin and Zyde
Raad from the Harvard School of Public Health say more
assessment is needed of such responsibilities; Geralyn
Ritter, Vice President of Global Public Policy and
Corporate Responsibility at Merck & Co. argues that
multiple stakeholders could do more to help States
deliver the right to health; and Paul Hunt and Rajat
Khosla introduce Mr. Hunt9s work as the UN Special
Rapporteur on the right to the highest attainable standard
of health, regarding the human rights responsibilities of
pharmaceutical companies and access to medicines.
This is the third of three viewpoints examining the question of whether
pharmaceutical companies are living up to their human rights
responsibilities.
Human Rights Guidelines for Pharmaceutical
Companies
In 2008, one of us (PH), serving as the UN Special Rapporteur
on the right to the highest attainable standard of health, submitted
a report to the UN General Assembly titled Human Rights Guidelines
for Pharmaceutical Companies in Relation to Access to Medicines [1]. The
Guidelines include a preamble, 47 guidelines, and a commentary.
All are based on the human rights principles set out in the
Universal Declaration of Human Rights, the international right to
the highest attainable standard of health codified in numerous
national constitutions and human rights treaties, and other widely
accepted standards such as some of those adopted by the World
Health Organisation (WHO) [2].
Emerging from a long process of research and consultation with
pharmaceutical companies and others—a process outlined in the
UN report of 2008—the Guidelines recognise some important
realities. For example: governments have the primary responsibil-
ity for increasing access to medicines; many health systems are
failing, constituting a grave obstacle to increasing access to
medicines; the pharmaceutical sector helps to save lives and
reduce suffering; and pharmaceutical companies have a respon-
sibility to enhance shareholder value.
But the Guidelines also reflect another equally important reality:
pharmaceutical companies have human rights responsibilities.
Critically, the Guidelines give content to these responsibilities, with
two vital implications. First, the Guidelines can and should help to
shape corporate policies, and second, they provide right-to-health
standards in relation to which companies can and should be held
accountable. The 47 guidelines are grouped in themes (Box 1
contains examples).
Pharmaceutical Patents and the Right to Health
In June 2008, PH made a formal UN right-to-health mission to
GlaxoSmithKline (GSK) that culminated in a report on the
company’s policies regarding access to medicines [3]. Although
distinct, the two projects—the Guidelines and the GSK report—
informed each other.
While the Guidelines apply to innovator, generic, and biotech-
nology companies, the GSK report had a particular preoccupation
with the right-to-health duties of innovator (i.e., patent-holding)
companies. The report emphasises that a pharmaceutical
company, having developed a life-saving medicine, has performed
a vitally important medical, public health, and right-to-health
function. The ‘‘reward’’ for fulfilling this critically important social
function is the grant of a patent—a limited monopoly—over the
relevant medicine, enabling the company to make a profit,
enhance shareholder value, and invest in further research and
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development. However, the company is granted a patent under
express and implied terms. Society has legitimate expectations of a
company holding the patent on a life-saving medicine. On the
basis of the goals of dignity and well-being of individuals and
communities, as well as of globally recognised standards, the right
to health clarifies, and gives substance to, these terms and
expectations. The agreement between society and the patent
holder of a life-saving medicine grants privileges to, and places
responsibilities on, the patent holder (Box 2).
When the right-to-health report on GSK was presented to the
UN Human Rights Council in 2009, the UK representative
commended the company for its full engagement with the Special
Rapporteur and continued: ‘‘While States bear responsibility for
ensuring that human rights are protected within their jurisdiction,
businesses should also ensure that they conduct their activities in a
manner that is consistent with enjoyment of human rights. The
Special Rapporteur rightly notes that progressively achieving
access to medicines for all who need them is an objective to which
both state and non-state actors can and should contribute.’’ The
UK delegate concluded: ‘‘We agree that pharmaceutical compa-
nies should support objective reporting on their access to
medicines commitments. We encourage them to develop ap-
proaches, such as external validation, to support this’’ [4].
Are Pharmaceutical Companies Living up to Their
Human Rights Obligations?
In an editorial headed ‘‘Right-to-health responsibilities of
pharmaceutical companies,’’ the editors of The Lancet observed in
2008 that the GSK report sets out ‘‘with reasonable precision how
the right to health, in the international code of human rights,
applies to the pharmaceutical industry.’’ The editorial went on to
say that ‘‘Pharmaceutical companies help deliver the right to
health. They save lives. But with this role comes responsibilities –
and companies must be better held to account in relation to those
responsibilities. The 2008 guidelines and the GSK report move us
closer to that goal’’ [5].
While many pharmaceutical companies are making an
indispensable contribution to improving access to medicines and
realising the right to health, they are not living up to all their
human rights responsibilities. In 2008, and again in 2010, the
Access to Medicine Index compared the efforts of 20 drug
companies in relation to access to medicines [6]. The Index scored
and ranked the companies on criteria such as public policy
influence and advocacy, pricing, patents and licensing, and
donation programmes. In 2008, GSK came out on top, followed
by NovoNordisk, Merck & Co., and Novartis. The bottom-ranked
companies were Pfizer, Wyeth, Teva Pharmaceutical, and
Schering-Plough. In 2010, Gilead Sciences replaced NovoNordisk
in the top four, and the bottom-ranked companies were Merck
KGaA, Takeda Pharmaceutical, Astellas Pharma, and Daiichi
Sankyo Co.
Although it does not explicitly adopt a human rights framework,
the Index reflects aspects of the Guidelines and the right to the
highest attainable standard of health, highlighting where compa-
nies are doing well in addition to some of their shortcomings. In
effect, the Index signals the degree to which the selected
companies are living up to some of their right-to-health obligations
and which have progressed and regressed. It shows that the record
is very mixed. As Wim Leereveld, the Index’s founder, put it when
launching the 2010 Index, ‘‘the industry as a whole still has a long
way to go.’’
The Special Rapporteur’s GSK report recognises some of the
company’s achievements, but also identifies some deficiencies. For
example, the report observes that while GSK deserves credit for
significantly reducing some of its prices, thereby enhancing access,
the price of Cervarix (HPV vaccine) ‘‘remains a cause of deep
concern’’ (para 66). The report notes that ‘‘GSK’s use of
Box 1. Human Rights Guidelines for
Pharmaceutical Companies in Relation to
Access to Medicines
Based on the human rights principles set out in the
Universal Declaration of Human Rights, the international
right to the highest attainable standard of health codified
in numerous national constitutions and human rights
treaties, and other widely accepted standards, the 47
guidelines are organised into themes. Some highlights:
N Guideline 5, which requires companies to give ‘‘particular
attention to the very poorest in all markets,’’ arises from
the human rights of equality and nondiscrimination.
N Guidelines 6–8, which include the rebuttable presump-
tion ‘‘in favour of the disclosure of information, held by
the company, which relates to access to medicines’’ is
based upon the human rights principle of transparency.
N Other guidelines apply transparency to the theme of
public policy influence, advocacy, and lobbying (guide-
lines 17–19).
N Guidelines 26–32 address patents and licensing, includ-
ing the vital role of commercial and noncommercial
voluntary licences.
N Guidelines 33–37 address pricing, such as differential
pricing between and within countries.
N Other themes include management, monitoring, and
accountability; neglected diseases; corruption; clinical
trials; ethical promotion and marketing; and public–
private partnerships.
Box 2. Right-to-Health Responsibilities of
Patent Holders of Life-Saving Medicines
N The seminal right-to-health responsibility is to take all
reasonable steps to make the medicine as accessible as
possible, as soon as possible, to all those in need, within
a viable business model.
N For example, as soon as the new medicine is marketed at
higher prices (usually in high-income countries), the
patent holder has a right-to-health responsibility to put
in place a range of mechanisms, such as differential
pricing between and within countries, to enhance access
for all those who cannot afford those prices. Also, the
patent holder has a right-to-health responsibility to
develop formulations for children, the elderly, pregnant
and lactating women, and extremes of climate.
N The agreement with society places a responsibility on
the patent holder to take these steps, expeditiously and
effectively, by way of deliberate, concrete, and targeted
measures.
N If the patent is worked without these steps being taken,
the patent holder is in breach of its right-to-health
responsibilities.
N The success of a patent holder’s actions will sometimes
depend upon states, donors. and others fulfilling their
responsibilities. Nonetheless, the patent holder has a
right-to-health responsibility to do what it can.
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commercial and non-commercial voluntary licences has signifi-
cantly enhanced access to some medicines,’’ observes that ‘‘GSK is
not using voluntary licensing enough,’’ and concludes it is
‘‘critically important that GSK enters into more commercial and
non-commercial voluntary licences across a range of medicines
and markets’’ (paras 78, 79, 81). The report recognises that
although ‘‘GSK is not usually considered to be an industry
hardliner on intellectual property issues, some of its positions, such
as those in India, Thailand and Philippines, undermine its
leadership position’’; thus the Special Rapporteur ‘‘urges GSK
to respect the right of countries to use, to the full, TRIPS [Trade-
Related aspects of Intellectual Property Rights] flexibilities and
encourages GSK to make a public commitment not to lobby for
TRIPS ‘plus’ standards’’ (para 82). The report commends GSK’s
appointment of an independent third party to externally assure
information in the access to medicines section of the company’s
Corporate Responsibility Report (2007), but ‘‘greatly regrets’’ the failure
to subject its next Corporate Responsibility Report to external assurance
(para 102).
The publications of UK’s Department for International
Development, Pharma Futures, the George Institute for Interna-
tional Health, Oxfam, WHO, Health Action International, Access
to Medicines Project, and others also tend to suggest that
pharmaceutical companies are not living up to their human rights
responsibilities [7–12]. Overall, we are left with the impression
that insufficiently differentiated prices between and within
countries, inadequate attention to research and development on
some neglected diseases, incomplete disclosure of financial support
for political candidates, inappropriate drug promotion, and
problematic clinical trials, are all commonplace within the
pharmaceutical sector. Crucially, they all represent a failure of
pharmaceutical companies to comply with the human rights
responsibilities set out in the Guidelines and the GSK report.
The Next Step: Effective Right-to-Health
Accountability Mechanisms
The apparent noncompliance of pharmaceutical companies
with their human rights responsibilities underscores the vital
importance of accountability mechanisms. Such mechanisms can
serve to check whether or not these allegations are well founded
and can make public, balanced, sensible determinations with
practical recommendations for all parties. Both the Guidelines and
the GSK report highlight the critical role of internal and external
(i.e., independent) mechanisms that not only monitor companies,
but also hold companies accountable for their right-to-health
responsibilities. If a company is serious about its responsibilities to
society, why not establish, for example, a corporate Ombuds with
oversight of its right-to-health responsibilities relating to access to
medicines? If courts are unable or unwilling to play this role, and if
neither states nor companies have the appetite to establish effective
right-to-health accountability mechanisms, then civil society must
take the initiative, as it always has in the implementation of human
rights.
In short, if others fail to act, a consortium of civil society
organisations should appoint a panel of well-respected global
leaders, supported by a small but properly resourced secretariat, to
monitor the policies and practices of pharmaceutical companies
and hold them publicly accountable for the discharge of their
right-to-health responsibilities.
Today, we have the right-to-health standards to which
pharmaceutical companies can be held accountable. The Access
to Medicine Index and other publications provide a firm
information base for monitoring the conduct of pharmaceutical
companies [6–12]. But, while standards and monitoring are
necessary, they are not sufficient. Now the challenge is to devise
effective, fair, and appropriate mechanisms by which companies
can be held publicly accountable for their right-to-health
responsibilities.
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